Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 32 of 32 publications.

Hellwig K, Magyari M, MacDonald TM, Cesta CE, Wergeland S, Leinonen MK, Ornoy A, Vukusic S, Lauer A, Zhou X, Kawai A, Weinrib R, Arana A, Boumenna T. A multi-country cohort database study to assess pregnancy and infant outcomes after potential maternal or paternal exposure to cladribine tablets in the treatment of multiple sclerosis: the CLEAR study methods and status update1. Ther Adv Neurol Disord. 2025 Jan 27;18:175628642. doi: 10.1177/17562864241310996

Benitez A, Andrews JS, Shah D, Mansfield C, Ross E, Rao S, Bussberg C, Galinksy J, Konermann-Bernhardt C, Lu M, Vass C. Caregiver preferences for dravet syndrome and lennox-gastaut syndrome treatments across the USA, UK, and Germany. Poster presented at the 2024 American Epilepsy Society (AES) Annual Meeting; December 7, 2024. Los Angeles, CA.

Mansfield C, Ho KA, Pierce A, Vass C, Liu X, Boroojerdi B, Kiri S. Patient preferences for myasthenia gravis treatments: a discrete-choice experiment. Poster presented at the American Academy of Neurology (AAN) Annual Meeting 2024; April 2024. Denver, CO. [abstract] Neurology. 2024 Apr 9; 102(17 Supplement 1). doi: 10.1212/WNL.0000000000206306

Mansfield C, Bullok K, Fuhs JV, Tockhorn-Heidenreich A, Andrews JS, DiBenedetti D, Matthews BR, Darling JC, Sutphin J, Hauber B. The patient voice: exploring treatment preferences in participants with mild cognitive concerns to inform regulatory decision making. Patient. 2022 Sep;15(5):551-64. doi: 10.1007/s40271-022-00576-w

Hauber B, Paulsen R, Callahan L, Potashman M, Lee D, Hartry A, Wunderlich G, Hoffman D, Wieberg D, Kremer I, DiBenedetti D. Quantifying what matters most to patients and care partners in Alzheimer's Disease. Poster presented at the 2020 Alzheimer's Association Virtual International Conference (AAIC); July 29, 2020.

Majid T, Paulsen R, Callahan L, Potashman M, Lee D, Hartry A, Wunderlich G, Hoffman D, Wieberg D, Kremer I, Hauber B, DiBenedetti D. The importance of care partner input in Alzheimer's Disease (AD) drug development. Poster presented at the 2020 Alzheimer's Association Virtual International Conference (AAIC); July 27, 2020.

Poulos C, Hauber B, Mirzaei F, Dilley A, DeMuro C, Fillit HM. A study of preferences for disease-modifying treatments for Alzheimer's Disease. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S278. doi: 10.1016/j.jval.2020.04.991

Poulos C, Wakeford C, Kinter E, Mange B, Schenk T, Jhaveri M. Patient and physician preferences for multiple sclerosis treatments in Germany: a discrete-choice experiment study. Mult Scler J Exp Transl Clin. 2020 Jan;9(2):1-14. doi: 10.1177/2055217320910778

Hauber B, DiBenedetti D, Vradenburg G, Callahan L, Potashman M, Krasa H, Hartry A, Wunderlich G, Hoffman D, Wieberg D, Kremer I. Identifying what matters to people with and at risk for Alzheimer's disease and their care partners: concept elicitation and item development. Poster presented at the 12th Clinical Trials in Alzheimer’s Disease (CTAD) Meeting; December 6, 2019. San Diego, CA.

Poulos C, Wakeford C, Kinter E, Mange B, Schenk T. Preferences of patients for features of injectable, oral, and infused disease-modifying treatments for relapse-remitting multiple sclerosis. Poster presented at the 2019 ISPOR Latin America Conference; September 13, 2019. Bogota, Colombia.

Poulos C, Wakeford C, Kinter E, Mange B, Schenk T. Preferences of German physicians for features of injectable, oral, and infused disease-modifying treatments for relapsing-remitting multiple sclerosis. Poster presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); October 10, 2018. Berlin, Germany.

Poulos C, Kinter E, van Beek J, Christensen K, Posner J. Preferences of patients with multiple sclerosis for attributes of injectable multiple sclerosis treatments in the United Kingdom and France. Int J Technol Assess Health Care. 2018 Jan;34(4):425-33. doi: 10.1017/S0266462318000491

Matharu M, Pascual J, Nisson Remahl I, Straube A, Lum A, Davar G, Odom D, Bennett L, Proctor C, Gutierrez L, Andrews E, Johannes C. Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe. Cephalalgia. 2017 Dec;37(14):1384-97. doi: 10.1177/0333102417724150

Mansfield C, Bullok KE, Fuhs JV, Kahle-Wrobleski K, Tockhorn-Heidenreich A, Andrews JS, DiBenedetti DB, Matthews BR, Darling JC, Siemers ER, Hauber AB. The patient voice: exploring treatment preferences in participants with mild cognitive concerns to inform regulatory decision-making. Poster presented at the 2017 Alzheimer’s Association International Conference; July 19, 2017. London, United Kingdom.

Luciano JV, D’Amico F, Feliu-Soler A, McCracken LM, Aguado J, Penarrubia-Maria MT, Knapp M, Serrano-Blanco A, Garcia-Campayo J. Cost-utility of group acceptance and commitment therapy for fibromyalgia versus recommended drugs: an economic analysis alongside a 6-month randomized controlled trial conducted in Spain (EFFIGACT Study). J Pain. 2017 Jul;18(7):868-80. doi: 10.1016/j.jpain.2017.03.001

Tell-Marti G, Puig-Butille JA, Potrony M, Plana E, Badenas C, Antonell A, Sanchez-Valle R, Molinuevo JL, Lleo A, Alcolea D, Fortea J, Fernandez-Santiago R, Clarimon J, Llado A, Puig S. A common variant in the MC1R gene (p.V92M) is associated with Alzheimer's disease risk. J Alzheimers Dis. 2017 Feb 3;56(3):1065-74. doi: 10.3233/JAD-161113

Poulos C, Kinter E, Yang J-C, Bridges JFP, Posner JD, Reder AT. Patient preferences for injectable treatments for multiple sclerosis in the United States: a discrete-choice experiment. Patient. 2016 Apr;9(2):171-80. doi: 10.1007/s40271-015-0136-x

Poulos C, Kinter E, Yang JC, Bridges JF, Posner J, Gleibner E, Muhlbacher A, Kieseier B. A discrete-choice experiment to determine patient preferences for injectable multiple sclerosis treatments in Germany. Ther Adv Neurol Disord. 2016 Mar;9(2):95-104. doi: 10.1177/1756285615622736.

Poulos C, Kinter E, Posner J, van Beek J. A comparison of stated preferences for injectable disease-modifying treatments for multiple sclerosis: compliant vs. non-compliant patients. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.

Mansfield CA, Sikirica M, Pugh A, Poulos C, Martin AA, Ruiz Moran L, Morano Larragueta R. Patient preferences for attributes of type 2 diabetes mellitus (T2DM) treatments in Spain. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.

Kinter E, van Beek J, Christensen K, Poulos C, Posner J, Sabatella G. Preferences of patients with multiple sclerosis for attributes of injectable MS treatments in the United Kingdom and France. Poster presented at the 1st Congress of the European Academy of Neurology; June 20, 2015. Berlin, Germany.

Alamo-Junquera D, Sunyer J, Iniguez C, Ballester F, Garcia-Esteban R, Forns J, Turner MC, Lertxundi A, Lertxundi N, Fernandez-Somoano A, Rodriquez-Dehli C, Julvez J. Prenatal head growth and child neuropsychological development at age 14 months. Am J Obstet Gynecol. 2015 May;212(5):661e1-e11. doi: 10.1016/j.ajog.2014.12.001

Matharu M, Pascual J, Nilsson Remahl I, Odom D, Gutierrez L, Andrews E, Largent J, Johannes C. EHMTI-0192. Onabotulinumtoxina prophylaxis in chronic migraine utilization and patient characteristics: observational study in the European Union. Poster presented at the 4th European Headache and Migraine Trust International Congress 2014; September 2014. Copenhagen, Denmark. [abstract] J. Headache Pain. 2014 Sep 18; 15(Suppl 1):G24. doi: 10.1186/1129-2377-15-S1-G24

Luciano JV, Barrada JR, Aguado J, Osma J, García-Campayo J. Bifactor analysis and construct validity of the HADS: a cross-sectional and longitudinal study in fibromyalgia patients. Psychological Assessment. 2014 Jun;26(2):395-406.

Poulos C, Kinter E, Yang JC, Bridges JFP, Posner JD, Reder A. United States multiple sclerosis patients' preferences for injectable treatments. Poster presented at the European Federation of Neurological Sciences - European Neurological Society Joint Congress of European Neurology; May 31, 2014.

Luciano JV, Guallar JA, Aguado J, López-Del-Hoyo Y, Olivan B, Magallón R, Alda M, Serrano-Blanco A, Gili M, García-Campayo J. Effectiveness of group acceptance and commitment therapy for fibromyalgia: a 6-month randomized controlled trial (EFFIGACT study). Pain. 2014 Apr;155(4):693-702.

Gonzalez JM, Johnson FR, Runken MC, Poulos CM. Evaluating migraineurs' preferences for migraine treatment outcomes using a choice experiment. Headache. 2013 Nov;53(10):1635-50.

Luciano JV, Aguado J, Serrano-Blanco A, Calandre EP, Rodriguez-Lopez CM. Dimensionality, reliability, and validity of the revised fibromyalgia impact questionnaire in two Spanish samples. Arthritis Care Res (Hoboken). 2013 Oct;65(10):1682-9.

Gonzalez J, Johnson R, Runken MC, Poulos C. Generalized healthy-time equivalents for migraine-treatment outcomes from choice-experiment trade-off preferences. Poster presented at the 2011 ISPOR 14th Annual European Congress; November 9, 2011.

Gaffney L, Sherrill EH, Wolowacz SE, Allen R, Connolly M. Predictors of health-related quality of life (HRQoL) in US patients suffering from rls. Poster presented at the International Congress on Parkinson's Disease and Movement Disorders; 2005.

Hauber BHIV, Candrilli SD, Snyder EG, McBurney CR. Validation of a model to assess long-term disease progression in alzheimer's disease patients treated with rivastigmine. Poster presented at the 9th International Conference on Alzheimer's Disease and Related Disorders; July 2004.

Hauber B, Candrilli S, Snyder EH, McBurney CR. Validation of a model to assess long-term disease progression in Alzheimer's disease patients treated with rivastigmine. Neurobiol Aging. 2004 Jan 1;25:S136.